Key facts
- EVerZom’s last known valuation is $9.2M (Jul 2025).
- It has raised $15.1M; the latest was Equity Crowdfunding ($1.0M) in Jul 2025.
- Notable investors include Bpifrance, European Innovation Council, La French Tech, Capital Grand Est, France 2030 — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for EVerZom
- ·The full record, as it builds
Funding rounds
No funding rounds for EVerZom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EVerZom
Developer of regenerative biologics treatment designed for tissue healing and organ restoration. The company integrates cell modification, high-yield exosome generation, molecular loading, and formulation processes, enabling healthcare professionals to access patent-protected extracellular vesicle therapeutics with enhanced therapeutic potency, improved biodistribution, reduced immunogenicity, and potential for application across digestive disorders and organ damage indications.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 20
- Website
- everzom.com/
- Ownership
- Privately Held (backing)
EVerZom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EVerZom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EVerZom in its N-PORT filings yet. We sweep new filings monthly.